Drug Trial Radar · NCT06453902
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 15, 2024
Primary completion
Jun 30, 2026
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University People's Hospital; Henan Cancer Hospital; Nanfang Hospital, Southern Medical University; The First Affiliated Hospital of Soochow University; Chinese Academy of Medical Sciences; First Affiliated Hospital of Zhejiang University; Shenzhen Second People's Hospital; Ruijin Hospital; Shengjing Hospital; Huazhong University of Science and Technology
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Conditions
- Chronic Myeloid Leukemia
- Accelerated Phase CML
Interventions
TGRX-678Drug
All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Hematologic Response (MaHR)Time frame: At screening, on Day 1 of every treatment cycle (each cycle is 28 days) and at end of treatment; average of study duration is 3.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.